Primary Image

generic image

Clinical Trial/Research Study

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

IRB Protocol Number STU00219033

Contact

nvg@sralab.org

Objective

This study is examining how the study drug, NVG-291, affects nerve connections in the spinal cord and whether it is safe and tolerable to use.

Volunteers in this study will:

  • Participate in study visits over 16 weeks.
  • Visits will take place at the Shirley Ryan AbilityLab.

Visit involves:  

  • Non-invasive stimulation of the brain and spinal cord and startle acoustic stimuli.
  • Upper and lower limb training
  • Answer questionnaire
  • Physiological and physical assessments
  • Receiving daily injections of NVG-291 or placebo.

Who Can Participate

Participants with a spinal cord injury who are:

  • Between 18-75 years of age
  • Sustained a spinal cord injury at C1-C7 (20-90 days post injury)
  • In good physical health
  • Proficiency in English

Compensation

Participants will receive compensation.

Apply for this Trial

Your information will not be published.

All fields are required.

Featured Quote

More Studies

Study On Thinking & Recovery After Traumatic Brain Injury

We are studying whether a non-invasive form of brain stimulation can improve memory and other thinking after a traumatic brain injury (TBI). Adults with a history of TBI are invited to join this study to help us learn how to better support recovery.

read more
view all

Latest Updates

view all